| Literature DB >> 34475704 |
Aradhana Marathe1, Gayathri M Rao1, M Chakrapani2.
Abstract
BACKGROUND AND AIM: Mucositis, one of the vulnerabilities of chemotherapy, affects the physiological activities and therapeutic strategies of patients because it can affect the normal cell population. Etoposide is a commonly used chemotherapeutic agent for cancers such as oral, lung, and gastrointestinal. In addition to the abnormal metabolic processes in the body caused by tumorigenesis, new metabolic alterations can occur, such as oxidative stress, antioxidant imbalance, and inflammatory reactions, all of which can contribute to existing patient vulnerability. Therapeutic adjuvants can help overcome these toxic effects. Spondias pinnata is a tropical tree omnipresent in the coastal and Western Ghat section of India that is used for culinary purposes and as a local analgesic. Therefore, we aimed to study the anti-inflammatory effects of S. pinnata in an etoposide-induced mucositis rat model.Entities:
Keywords: etoposide; mucositis; oxidative and inflammatory markers
Year: 2021 PMID: 34475704 PMCID: PMC8404108 DOI: 10.14202/vetworld.2021.1822-1828
Source DB: PubMed Journal: Vet World ISSN: 0972-8988
MPO activity.
| Groups | MPO activity (U/L) (Mean±SEM) | p-value between individual groups and normal group by independent sample t-test | p-value between EP, SP, and EP+SP groups, respectively, by ANOVA |
|---|---|---|---|
|
|
| ||
| Normal (1) | 56.67±6.97 | ||
| EP 24 h (2a) | 53.22±9.01 | 0.767 | <0.001* |
| EP 48 h (2b) | 89.27±7.38 | 0.00861* | |
| EP 72 h (2c) | 91.71±6.04 | 0.00486* | |
| EP 96 h (2d) | 97.19±4.38 | <0.001* | |
| SP 24 h (3a) | 54.13±1.04 | 0.727 | 0.0017* |
| SP 48 h (3b) | 53.02±0.51 | 0.614 | |
| SP 72 h (3c) | 41.01±1.79 | 0.055 | |
| SP 96 h (3d) | 39.48±0.79 | 0.0344* | |
| EP±SP 24 h (4a) | 68.44±2.18 | 0.138 | 0.255 |
| EP±SP 48 h (4b) | 66.26±3.88 | 0.258 | |
| EP±SP 72 h (4c) | 62.46±2.54 | 0.453 | |
| EP ±SP 96 h (4d) | 58.05±3.33 | 0.872 | |
| Comparison between normal and 24 h after treatment groups | 0.161 | ||
| Comparison between normal and 48 h after treatment groups | <0.001* | ||
| Comparison between normal and 72 h after treatment groups | <0.001* | ||
| Comparison between normal and 96 h after treatment groups | <0.001* | ||
MPO=Myeloperoxidase, SEM=Standard error of the mean, ANOVA=Analysis of variance
Nitric oxide levels.
| Groups | NO concentration (mg/g tissue) (Mean±SEM) | p-value between individual groups and normal group by independent sample t-test | p-value between EP, SP, and EP+SP groups, respectively, by ANOVA |
|---|---|---|---|
|
|
| ||
| Normal (1) | 14.35±0.77 | ||
| EP 24 h (2a) | 18.42±0.64 | 0.00597* | <0.001* |
| EP 48 h (2b) | 28.33±0.33 | <0.001* | |
| EP 72 h (2c) | 67.87±3.57 | <0.001* | |
| EP 96 h (2d) | 98.82±2.19 | <0.001* | |
| SP 24 h (3a) | 12.51±1.33 | 0.26 | 0.396 |
| SP 48 h (3b) | 12.37±0.54 | 0.0638 | |
| SP 72 h (3c) | 11.295±0.53 | 0.00878* | |
| SP 96 h (3d) | 11.205±0.35 | 0.0042* | |
| EP±SP 24 h (4a) | 70.02±3.9 | <0.001* | <0.001* |
| EP±SP 48 h (4b) | 57.10±5.63 | <0.001* | |
| EP±SP 72 h (4c) | 53.37±4.90 | <0.001* | |
| EP±SP 96 h (4d) | 47.736±2.72 | <0.001* | |
| Comparison between normal and 24 h after treatment groups | <0.001* | ||
| Comparison between normal and 48 h after treatment groups | <0.001* | ||
| Comparison between normal and 72 h after treatment groups | <0.001* | ||
| Comparison between normal and 96 h after treatment groups | <0.001* | ||
NO=Nitric oxide, SEM=Standard error of the mean, ANOVA=Analysis of variance
TAO activity.
| Groups | TAO activity (mM/L) (Mean±SEM) | p-value between individual groups and normal group by independent sample t-test | p-value between EP, SP, and EP+SP groups, respectively, by ANOVA |
|---|---|---|---|
|
|
| ||
| Normal (1) | 8.91±0.13 | ||
| EP 24 h (2a) | 8.0±0.2 | 0.00463* | <0.001* |
| EP 48 h (2b) | 6.52±0.16 | <0.001* | |
| EP 72 h (2c) | 4.58±0.08 | <0.001* | |
| EP 96 h (2d) | 2.72±0.31 | <0.001* | |
| SP 24 h (3a) | 8.48±0.14 | 0.0518 | 0.0272* |
| SP 48 h (3b) | 8.96±0.09 | 0.771 | |
| SP 72 h (3c) | 8.98±0.10 | 0.708 | |
| SP 96 h (3d) | 9.01±0.08 | 0.708 | |
| EP±SP 24 h (4a) | 6.73±0.2 | <0.001* | <0.001* |
| EP±SP 48 h (4b) | 7.55±0.14 | <0.001* | |
| EP±SP 72 h (4c) | 8.36±0.10 | 0.00885* | |
| EP±SP 96 h (4d) | 8.60±0.04 | 0.0794 | |
| Comparison between normal and 24 h after treatment groups | <0.001* | ||
| Comparison between normal and 48 h after treatment groups | <0.001* | ||
| Comparison between normal and 72 h after treatment groups | <0.001* | ||
| Comparison between normal and 96 h after treatment groups | <0.001* | ||
TAO=Total antioxidant, SEM=Standard error of the mean, ANOVA=Analysis of variance
GSH levels.
| Groups | GSH levels (mg/g tissue) (Mean±SEM) | p-value (in comparison with normal group) by independent sample t-test | p-value between EP, SP, and EP+SP groups, respectively, obtained by ANOVA |
|---|---|---|---|
|
|
| ||
| Normal (1) | 206.54±5.64 | ||
| EP 24 h (2a) | 169.66±2.98 | 0.001* | <0.001 |
| EP 48 h (2b) | 148.16±4.72 | <0.001* | |
| EP 72 h (2c) | 133.24±7.03 | <0.001* | |
| EP 96 h (2d) | 105.90±11.49 | <0.001* | |
| SP 24 h (3a) | 195.35±3.31 | 0.118 | <0.001 |
| SP 48 h (3b) | 200.95±5.18 | 0.482 | |
| SP 72 h (3c) | 216.69±0.99 | 0.107 | |
| SP 96 h (3d) | 222.70±2.82 | 0.0284* | |
| EP±SP 24 h (4a) | 109.59±4.02 | <0.001* | <0.001 |
| EP±SP 48 h (4b) | 132.17±1.88 | <0.001* | |
| EP±SP 72 h (4c) | 142.53±1.77 | <0.001* | |
| EP ±SP 96 h (4d) | 159.60±2.62 | <0.001* | |
| Comparison between normal and 24 h after treatment groups | <0.001* | ||
| Comparison between normal and 48 h after treatment groups | <0.001* | ||
| Comparison between normal and 72 h after treatment groups | <0.001* | ||
| Comparison between normal and 96 h after treatment groups | <0.001* | ||
GSH=Glutathione, SEM=Standard error of the mean, ANOVA=Analysis of variance
Na+-K+ ATPase activity.
| Groups | Na+-K+ ATPase activity (U/L) Median (Q1, Q2) | p-value between individual groups and normal group obtained by Mann–Whitney U-test | p-value between EP, SP, and EP+SP groups, respectively, obtained by Kruskal–Wallis rank-sum test |
|---|---|---|---|
|
|
| ||
| Normal (1) | 0.36 (0.22, 0.39) | ||
| EP 24 h | 0.16(0.07,0.27) | 0.352 | 0.05 |
| EP 48 h | 0.47 (0.23,1.31) | 0.36 | |
| EP 72 h | 0.50 (0.34, 0.53) | 0.329 | |
| EP 96 h | 0.67 (0.60,0.88) | 0.00952* | |
| SP 24 h | 0.25 (0.22,0.27) | 0.336 | 0.3215 |
| SP 48 h | 0.27 (0.24, 0.28) | 0.378 | |
| SP 72 h | 0.32 (0.30,0.33) | 0.394 | |
| SP 96 h | 0.32(0.25,0.36) | 0.873 | |
| EP±SP 24 h | 0.25 (0.23, 0.27) | 0.429 | 0.0275 |
| EP±SP 48 h | 0.26 (.24,0.27) | 0.394 | |
| EP±SP 72 h | 0.28 (0.26,0.30) | 0.378 | |
| EP±SP 96 h | 0.36 (0.34,0.38) | 0.927 | |
| Comparison between normal and 24 h after treatment groups | 0.5445 | ||
| Comparison between normal and 48 h after treatment groups | 0.651 | ||
| Comparison between normal and 72 h after treatment groups | 0.197 | ||
| Comparison between normal and 96 h after treatment groups | 0.0197* | ||